Bicycle Therapeutics (BCYC) Accumulated Expenses (2018 - 2026)

Bicycle Therapeutics (BCYC) has 9 years of Accumulated Expenses data on file, last reported at $39.1 million in Q2 2026.

• Quarterly Accumulated Expenses fell 12.22% year-over-year to $39.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $39.1 million (down 12.22% YoY) and the FY2025 annual result came in at $44.4 million, up 7.54% from the prior year.
• Accumulated Expenses eased to $39.1 million in Q2 2026, from $40.1 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $44.5 million in Q2 2025 to a low of $12.3 million in Q1 2022.
• A 5-year average of $32.4 million and a median of $34.0 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses soared 119.81% — and 2024, when it dropped 24.49%.
• Tracing BCYC's Accumulated Expenses over 5 years: stood at $26.5 million in 2022, then rose by 19.12% to $31.5 million in 2023, then soared by 30.9% to $41.2 million in 2024, then climbed by 7.54% to $44.4 million in 2025, then slipped by 11.86% to $39.1 million in 2026.
• The last three Accumulated Expenses figures came in at $39.1 million (Q2 2026), $40.1 million (Q1 2026), and $44.4 million (Q4 2025), per Business Quant data.